NanoString Technologies, Inc. (NSTG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NanoString Technologies, Inc. (NSTG) trades at $0.11 with AI Score 51/100 (Grade B). NanoString Technologies, Inc. focuses on developing and commercializing genomic and proteomic analysis tools for scientific and clinical research. Market cap: $5.07M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for NSTG: NSTG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NSTG against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NSTG: the 1 perspectives are evenly split.
How is this calculated? →NanoString Technologies, Inc. (NSTG) Healthcare & Pipeline Overview
NanoString Technologies, Inc., a player in the medical instruments and supplies sector, provides innovative tools for genomic and proteomic analysis, including the nCounter Analysis System and GeoMx Digital Spatial Profiler, catering to the scientific and clinical research communities across the Americas, Europe, the Middle East, and Asia Pacific.
What Is the Investment Thesis for NSTG?
NanoString Technologies operates in the growing genomics and proteomics analysis market, with its nCounter and GeoMx platforms offering unique capabilities for spatial biology. Despite a current negative profit margin of -125.4%, the company maintains a gross margin of 48.6%, indicating potential for profitability with increased scale and cost management. Key growth catalysts include the expansion of GeoMx DSP system adoption and continued development of oncology and immunology applications. The company's collaborations with Lam Research, Celgene, and the Parker Institute for Cancer Immunotherapy represent potential value drivers. However, the company's small market capitalization of $5.07M and high beta of 1.24 suggest higher volatility and risk.
Based on FMP financials and quantitative analysis
NSTG Key Highlights
- Market Cap of $5.07M reflects the company's current valuation in the market.
- Profit Margin of -125.4% indicates that the company is currently operating at a loss.
- Gross Margin of 48.6% suggests potential for profitability with improved cost management and increased sales.
- Beta of 1.24 indicates that the stock is more volatile than the market average.
- No dividend is paid, which is typical for growth-oriented companies in the biotechnology sector.
Who Are NSTG's Competitors?
NSTG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ILMN Illumina, Inc. | $193.81 | -0.27% | $29.32B | 91 |
| TMO Thermo Fisher Scientific Inc. | $513.65 | -0.76% | $190.88B | 61 |
| DHR Danaher Corporation | $193.72 | +0.05% | $137.11B | 69 |
| NYXH Nyxoah S.A. | $1.62 | -8.47% | $64.16M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $28.08 | +0.73% | $1.64B | 67 |
| ZTEK Zentek Ltd. | $0.51 | +10.73% | $55.26M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| TRUMY Terumo Corporation | $14.27 | +1.26% | $21.05B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NSTG's Key Strengths?
- Innovative technology platforms (nCounter, GeoMx DSP)
- Established presence in spatial genomics
- Strategic collaborations with key industry players
- Diverse product portfolio catering to various research applications
What Are NSTG's Weaknesses?
- Negative profit margin
- Small market capitalization
- High beta indicating volatility
- Dependence on research and development success
What Could Drive NSTG Stock Higher?
- Expansion of GeoMx DSP system adoption and applications.
- Development of new oncology and immunology assays.
- Potential regulatory approvals for new diagnostic products.
- Continued strategic collaborations with pharmaceutical companies and research institutions.
What Are the Key Risks for NSTG?
- Financial-distress signal — its Altman Z-Score of -5.48 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger, more established companies in the genomics and proteomics market.
- Regulatory hurdles and approval processes for new diagnostic products.
- Economic downturn affecting research funding and customer spending.
- Technological obsolescence and the need for continuous innovation.
- Dependence on key partnerships and collaborations for product development and market access.
What Are the Growth Opportunities for NSTG?
- Expansion of GeoMx Digital Spatial Profiler (DSP) Adoption: The GeoMx DSP system enables spatial genomics, a rapidly growing field. By expanding the applications and user base of GeoMx DSP, NanoString can tap into a significant market opportunity. The spatial biology market is projected to reach billions of dollars in the coming years, driven by the increasing need for understanding cellular interactions within tissues. Timeline: Ongoing, with continuous product development and market expansion efforts.
- Development of New Oncology Applications: Oncology remains a key area of focus for NanoString. Developing new applications and assays for cancer research and diagnostics can drive revenue growth. The global oncology market is substantial and growing, with continuous demand for innovative diagnostic and therapeutic solutions. Timeline: Ongoing, with continuous research and development efforts.
- Strategic Partnerships and Collaborations: Collaborations with pharmaceutical companies, research institutions, and other organizations can provide access to new markets, technologies, and funding. NanoString's existing partnerships with Lam Research, Celgene, and the Parker Institute for Cancer Immunotherapy demonstrate the potential of this strategy. Timeline: Ongoing, with continuous exploration of new partnership opportunities.
- Geographic Expansion: Expanding sales and marketing efforts into new geographic regions, particularly in Asia Pacific, can drive revenue growth. The Asia Pacific region is experiencing rapid growth in the life sciences and healthcare sectors, presenting a significant market opportunity for NanoString's products and services. Timeline: Ongoing, with targeted expansion efforts in key markets.
- Advancements in Proteomics: Leveraging its expertise in genomics to expand its offerings in proteomics can create new revenue streams. Proteomics is a complementary field to genomics, and the demand for proteomics tools and services is growing. NanoString can develop new assays and platforms for protein analysis, addressing the needs of researchers and clinicians. Timeline: Ongoing, with continuous research and development efforts.
What Opportunities Does NSTG Have?
- Expansion of GeoMx DSP adoption
- Development of new oncology applications
- Geographic expansion into Asia Pacific
- Advancements in proteomics
What Threats Does NSTG Face?
- Competition from larger, more established companies
- Regulatory hurdles and approval processes
- Economic downturn affecting research funding
- Technological obsolescence
What Are NSTG's Competitive Advantages?
- Proprietary Technology: The nCounter Analysis System and GeoMx DSP system utilize unique technologies for digital detection and spatial genomics.
- Established Customer Base: NanoString has built a customer base in academic, pharmaceutical, and clinical research markets.
- Strategic Partnerships: Collaborations with leading organizations provide access to new markets and technologies.
- Intellectual Property: Patents and other intellectual property protect the company's technologies and products.
What Does NSTG Do?
NanoString Technologies, Inc., founded in 2003 and headquartered in Seattle, Washington, is dedicated to the development, manufacture, and sale of advanced tools for scientific and clinical research, specifically in the fields of genomics and proteomics. The company's flagship product, the nCounter Analysis System, is an automated, multi-application platform that digitally detects and counts molecules. This system is complemented by the nCounter MAX and FLEX systems, which include the Prep Station for automated sample processing and the nCounter Digital Analyzer for data collection and analysis. NanoString also offers the nCounter SPRINT Profiler, a compact instrument utilizing microfluidic cartridges for streamlined analysis. The company's nSolver Analysis Software provides researchers with tools to normalize, check, and analyze their data. Beyond instrumentation, NanoString offers custom CodeSets and panels tailored for oncology, immunology, infectious disease, and neuroscience applications. The company also provides Master Kits, including reagents and plasticware, and the Prosigna molecular diagnostic test kits. NanoString is actively developing the GeoMx DSP system to advance the field of spatial genomics. Strategic collaborations include partnerships with Lam Research Corporation for Hyb & Seq technology development, Celgene Corporation for the LymphMark in vitro diagnostic for diffuse large B-cell lymphoma, and the Parker Institute for Cancer Immunotherapy to enhance CAR-T regimens for cancer treatment.
What Products and Services Does NSTG Offer?
- Develops and manufactures tools for genomic and proteomic analysis.
- Offers the nCounter Analysis System for automated digital detection and counting of molecules.
- Provides nCounter MAX and FLEX systems for sample processing and data collection.
- Offers the nCounter SPRINT Profiler for streamlined analysis using microfluidic cartridges.
- Provides nSolver Analysis Software for data normalization, checking, and analysis.
- Offers custom CodeSets and panels for oncology, immunology, infectious disease, and neuroscience applications.
- Develops the GeoMx DSP system for spatial genomics.
How Does NSTG Make Money?
- Sells instruments and systems like the nCounter Analysis System and GeoMx DSP.
- Generates revenue from the sale of consumables, such as CodeSets, panels, and Master Kits.
- Offers software and data analysis services through nSolver Analysis Software.
- Forms strategic collaborations and partnerships to develop new products and expand market reach.
What Industry Does NSTG Operate In?
NanoString Technologies operates within the medical instruments and supplies industry, a segment driven by advancements in genomics, proteomics, and spatial biology. The market is characterized by increasing demand for precision medicine and personalized healthcare solutions. NanoString's focus on spatial genomics with its GeoMx DSP system positions it within a high-growth area. The competitive landscape includes companies offering similar analysis tools and services, requiring NanoString to differentiate through innovation, strategic partnerships, and market penetration.
Who Are NSTG's Key Customers?
- Academic research institutions
- Pharmaceutical and biotechnology companies
- Clinical research laboratories
- Government research agencies
Net sellingInsider Activity
The most recent 12 insider filings for NanoString Technologies, Inc. break down as 5 sales and 7 purchases. On net that is roughly 18K shares disposed (about $0), a signal worth weighing alongside the fundamentals.
FY2026 estForward Outlook
Wall Street analysts project NanoString Technologies, Inc. revenue of about $273.3M for fiscal 2026, with EPS near $-0.64. The estimate reflects 5 contributing analysts.
F-Score 2/9Financial Health
NanoString Technologies, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.48 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -45.1%, showing how much profit it generates from its asset base. A current ratio of 4.87 indicates the company holds enough short-term assets to cover its near-term obligations.
NanoString Technologies, Inc. (NSTG) Valuation Context
Valued at $5.07M, NSTG is classified as a micro-cap stock. Relative to its peer group, NSTG's quantitative score of 51/100 is below the peer average of 71/100.
Company Profile
NanoString Technologies, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO R. Bradley Gray. NSTG has traded publicly since 2013.
NSTG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative technology platforms (nCounter, GeoMx DSP)
- Established presence in spatial genomics
- Strategic collaborations with key industry players
- Diverse product portfolio catering to various research applications
Bear Case
- Negative profit margin
- Small market capitalization
- High beta indicating volatility
- Dependence on research and development success
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NSTG Latest News
-
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
benzinga · Jul 10, 2023
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Oct 24, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Oct 11, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Jun 14, 2022
NSTG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NSTG.
Price Targets
Wall Street price target analysis for NSTG.
NSTG MoonshotScore
What does this score mean?
The MoonshotScore rates NSTG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Why Icahn Enterprises Shares Are Trading Higher By 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Tuesday
Stocks That Hit 52-Week Lows On Tuesday
Leadership: R. Bradley Gray
President and Chief Executive Officer
R. Bradley Gray serves as the President and Chief Executive Officer of NanoString Technologies, Inc. His background includes extensive experience in the life sciences and diagnostics industries. Prior to joining NanoString, he held leadership positions at companies such as Genzyme and Cytyc Corporation. His expertise spans commercial operations, strategic planning, and business development. He has a proven track record of driving growth and innovation in the healthcare sector.
Track Record: Under R. Bradley Gray's leadership, NanoString Technologies has focused on expanding its spatial genomics capabilities and strengthening its market position. Key achievements include the commercialization of the GeoMx DSP system and the establishment of strategic partnerships. He has also overseen the company's efforts to develop new applications and assays for oncology and immunology. His tenure has been marked by a focus on innovation and market expansion.
Common Questions About NSTG (Healthcare)
What does NanoString Technologies, Inc. do?
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics. The company's primary offerings include the nCounter Analysis System, an automated platform for digital detection and counting of molecules, and the GeoMx Digital Spatial Profiler (DSP) system, which enables spatial genomics analysis. These tools are used by researchers and clinicians to study gene expression, protein expression, and other biological processes, with applications in oncology, immunology, and other areas. NanoString's business model involves selling instruments, consumables, and software to academic, pharmaceutical, and clinical research customers.
What do analysts say about NSTG stock?
Analyst coverage of NanoString Technologies, Inc. typically focuses on the company's growth potential in the spatial genomics market and the adoption of its GeoMx DSP system. Key valuation metrics include revenue growth, gross margin, and operating expenses. Analyst consensus generally reflects expectations for continued revenue growth driven by new product launches and market expansion. However, analysts also consider the company's profitability challenges and the competitive landscape. Analyst ratings and price targets vary depending on individual firm's assessments of the company's prospects and risks. It is important to consult multiple sources of analyst research and conduct independent due diligence before making investment decisions.
What are the main risks for NSTG?
NanoString Technologies, Inc. faces several risks, including competition from larger, more established companies in the genomics and proteomics market, such as Illumina and Thermo Fisher Scientific. Regulatory hurdles and approval processes for new diagnostic products can also pose a risk. An economic downturn could affect research funding and customer spending, impacting the company's revenue. Technological obsolescence is another risk, requiring continuous innovation to maintain a competitive edge. Dependence on key partnerships and collaborations for product development and market access also presents a risk, as the loss of a key partner could negatively impact the company's prospects.
What are the key factors to evaluate for NSTG?
NanoString Technologies, Inc. (NSTG) holds an AI score of 51/100 (moderate). Not financial advice.
How frequently does NSTG data refresh on this page?
NSTG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NSTG's recent stock price performance?
NanoString Technologies, Inc. (NSTG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platforms (nCounter, GeoMx DSP). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NSTG overvalued or undervalued right now?
Valuing NanoString Technologies, Inc. (NSTG) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NSTG?
Before investing in NanoString Technologies, Inc. (NSTG), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Financial data is based on the most recent available reports.